AR017021A1 - Acido 2-hidroxiacetico - Google Patents

Acido 2-hidroxiacetico

Info

Publication number
AR017021A1
AR017021A1 ARP980104219A ARP980104219A AR017021A1 AR 017021 A1 AR017021 A1 AR 017021A1 AR P980104219 A ARP980104219 A AR P980104219A AR P980104219 A ARP980104219 A AR P980104219A AR 017021 A1 AR017021 A1 AR 017021A1
Authority
AR
Argentina
Prior art keywords
diseases
difluorocyclopentyl
salts
useful
compound
Prior art date
Application number
ARP980104219A
Other languages
English (en)
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of AR017021A1 publication Critical patent/AR017021A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere al ácido 2-hidroxiacético de formula general (III), donde Ar es fenilo, y R10 representa 3,3-difluorociclopentilo y sus sales. Enparticular la invencion se refiere al ácido (2R)-2-[(1R)-3,3-difluorociclopentil]-2-hidroxi-2-fenilacético y sus sales. El compuesto de la invencion esutil como reactivo para preparar derivados de piperidina 1,4-disustituida que contiene fluor. Los derivados preparados a partir del compuesto de lainvencion tienen no solo un antagonismo potente y selectivo para los receptores M3 muscarínicos sino también tienen pocos efectos colaterales. Más aun,exhiben una excelente actividad oral, duracion de accion y farmacocinética. Por lo tanto son utiles para el tratamiento y profilaxis de las enfermedadesrespiratorios, las enfermedades urinarias y las enfermedades digestivas.
ARP980104219A 1996-08-01 1998-08-25 Acido 2-hidroxiacetico AR017021A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21943696 1996-08-01
JP5397997 1997-02-21

Publications (1)

Publication Number Publication Date
AR017021A1 true AR017021A1 (es) 2001-08-22

Family

ID=26394715

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP970103516A AR008272A1 (es) 1996-08-01 1997-08-01 Derivados de piperidina 1,4-disustituida que contienen fluor, composicion farmaceutica compuesta de los mismos y un proceso para su preparacion
ARP980104218A AR016877A2 (es) 1996-08-01 1998-08-25 6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales
ARP980104219A AR017021A1 (es) 1996-08-01 1998-08-25 Acido 2-hidroxiacetico

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP970103516A AR008272A1 (es) 1996-08-01 1997-08-01 Derivados de piperidina 1,4-disustituida que contienen fluor, composicion farmaceutica compuesta de los mismos y un proceso para su preparacion
ARP980104218A AR016877A2 (es) 1996-08-01 1998-08-25 6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales

Country Status (29)

Country Link
US (2) US5948792A (es)
EP (1) EP0930298B1 (es)
JP (1) JP3063164B2 (es)
KR (1) KR20000022214A (es)
CN (1) CN1226888A (es)
AR (3) AR008272A1 (es)
AT (1) ATE229941T1 (es)
AU (1) AU716050B2 (es)
BG (1) BG103114A (es)
BR (1) BR9711108A (es)
CA (1) CA2261680C (es)
CO (1) CO4960641A1 (es)
CZ (1) CZ33199A3 (es)
DE (1) DE69718026T2 (es)
EE (1) EE9900038A (es)
ES (1) ES2188961T3 (es)
HR (1) HRP970426A2 (es)
HU (1) HUP9902381A3 (es)
ID (1) ID17259A (es)
IL (1) IL127685A0 (es)
IS (1) IS4960A (es)
NO (1) NO990472D0 (es)
NZ (1) NZ333842A (es)
PE (1) PE92198A1 (es)
PL (1) PL331431A1 (es)
SK (1) SK12299A3 (es)
TR (2) TR199900204T2 (es)
WO (1) WO1998005641A1 (es)
YU (1) YU1299A (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180823B1 (en) 1998-11-06 2001-01-30 Sepracor Inc. Stereoselective process for alkyl phenylglycolic acids
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
WO2000061572A1 (en) 1999-04-08 2000-10-19 Merck & Co., Inc. Diastereoselective preparation of michael adducts
WO2000066579A1 (fr) * 1999-04-28 2000-11-09 Banyu Pharmaceutical Co., Ltd. Methodes de preparation de derives de piperidylmethylpyridine
WO2001013918A1 (en) * 1999-08-23 2001-03-01 H. Lundbeck A/S Treatment of urinary incontinence
AU783095B2 (en) * 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
EP1242083B1 (fr) * 1999-12-17 2007-03-14 Sanofi-Aventis Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6469172B2 (en) 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
SK8002003A3 (en) 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
AU2002238471B2 (en) 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
CN1558756A (zh) * 2001-09-27 2004-12-29 �ź㴫 用于治疗泌尿疾病的药物组合物
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
EP1546099B1 (en) 2002-07-08 2008-12-31 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
EP1546098B1 (en) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (en) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
US6583103B1 (en) 2002-08-09 2003-06-24 S.C. Johnson & Son, Inc. Two part cleaning formula resulting in an effervescent liquid
DE60231341D1 (de) 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
EP1562599A1 (en) * 2002-10-29 2005-08-17 Pharmacia & Upjohn Company LLC Quaternary ammonium compounds as muscarinic receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
WO2004052857A1 (en) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
WO2004056767A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
WO2004056811A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089899A1 (en) * 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100406009C (zh) 2003-04-10 2008-07-30 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的取代的氮杂双环己烷衍生物
BRPI0409302A (pt) * 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
WO2005007645A1 (en) 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
ATE435855T1 (de) 2003-11-21 2009-07-15 Theravance Inc Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor
WO2005063738A1 (ja) * 2003-12-29 2005-07-14 Banyu Pharmaceutical Co.,Ltd 新規２－へテロアリール置換ベンズイミダゾール誘導体
ATE419246T1 (de) * 2004-06-16 2009-01-15 Ranbaxy Lab Ltd Als antagonisten des muscarinrezeptors geeignete xanthinderivate
US20080262075A1 (en) * 2004-08-19 2008-10-23 Ranbaxy Laboratories Limited Pyrrolidine Derivatives as Muscarinic Receptor Antagonists
US20080280883A1 (en) * 2004-09-24 2008-11-13 Mohammad Salman Muscarinic Receptor Antagonists
EP1797040A1 (en) * 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN101094847B (zh) 2004-11-02 2011-06-15 Msdk.K.公司 芳氧基取代的苯并咪唑衍生物
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
US7799820B2 (en) * 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
EP1934184A1 (en) * 2005-10-05 2008-06-25 Ranbaxy Laboratories, Ltd. 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
CA2697752C (en) * 2007-09-07 2016-01-26 Theravance, Inc. Guanidine-containing compounds useful as muscarinic receptor antagonists
PT2234600E (pt) * 2007-12-21 2014-09-25 Hoffmann La Roche Formulação de anticorpos
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 １−（１，３−ジオキソラン−４−イルメチル）ピペリジノ−ル誘導体
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
US5750540A (en) * 1995-04-28 1998-05-12 Banyu Pharmaceutical Co., Ltd. 1,4-di-substituted piperidine derivatives
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate

Also Published As

Publication number Publication date
CN1226888A (zh) 1999-08-25
ES2188961T3 (es) 2003-07-01
IS4960A (is) 1999-01-29
EP0930298A4 (en) 2000-06-07
SK12299A3 (en) 2000-05-16
PL331431A1 (en) 1999-07-19
ID17259A (id) 1997-12-11
PE92198A1 (es) 1999-01-09
BR9711108A (pt) 1999-08-17
TR199900204T2 (xx) 2000-01-21
US5948792A (en) 1999-09-07
HUP9902381A3 (en) 2000-06-28
CZ33199A3 (cs) 1999-07-14
HUP9902381A2 (hu) 1999-11-29
AU3635197A (en) 1998-02-25
NO990472L (no) 1999-02-01
CO4960641A1 (es) 2000-09-25
CA2261680A1 (en) 1998-02-12
US6040449A (en) 2000-03-21
TR200001482T2 (tr) 2000-11-21
HRP970426A2 (en) 1998-08-31
EP0930298B1 (en) 2002-12-18
YU1299A (sh) 2002-03-18
IL127685A0 (en) 1999-10-28
JP3063164B2 (ja) 2000-07-12
CA2261680C (en) 2005-03-08
WO1998005641A1 (fr) 1998-02-12
BG103114A (en) 1999-11-30
DE69718026D1 (de) 2003-01-30
NO990472D0 (no) 1999-02-01
NZ333842A (en) 2001-05-25
AR016877A2 (es) 2001-08-01
ATE229941T1 (de) 2003-01-15
AR008272A1 (es) 1999-12-29
EE9900038A (et) 1999-08-16
AU716050B2 (en) 2000-02-17
KR20000022214A (ko) 2000-04-25
EP0930298A1 (en) 1999-07-21
DE69718026T2 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
AR017021A1 (es) Acido 2-hidroxiacetico
AR031828A2 (es) Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia
UY26872A1 (es) Derivados de la 4- fenil piridina
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
CY1106784T1 (el) Υποκατεστημενα παραγωγα φαινυλ προπιονικου οξεος ως συναγωνιστες του ανθρωπινου υπεροξυσωματικου πολλαπλασιαστη - ενεργοποιημενου υποδοχεα αλφα (ppar)
PA8591701A1 (es) Derivados de pirrolopirimidina
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
AR031680A1 (es) Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
SE0200979D0 (sv) New compounds
BR0016747A (pt) Bases de mannich de indol substituìdas
ATE557002T1 (de) Verbindungen mit calcimimetischer wirkung
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
UY26098A1 (es) Proceso para preparar derivados de ácidos ariloxiarilsulfonilamino hidroxamicos
EA200100841A1 (ru) Оксаминовые кислоты и их производные в качестве лигандов тиреоидных рецепторов
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
RU2007142328A (ru) Производные тиоксантина в качестве ингибиторов миелопероксидазы
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
MEP41408A (en) Novel diphenyl azetidinone with improved physiological characteristics, corresponding production method, medicaments containing said compound and use of the latter
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
UY27786A1 (es) Derivados de isoquinolina.
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.